Evidence map›Paper›PMID 36494364›Full record

ArticleNature communications2022

Meteorin-like is an injectable peptide that can enhance regeneration in aged muscle through immune-driven fibro/adipogenic progenitor signaling.

David E Lee, Lauren K McKay, Akshay Bareja, Yongwu Li, Alastair Khodabukus, Nenad Bursac, Gregory A Taylor, Gurpreet S Baht, James P White

Open access · goldAbstract read
In one paragraph

Article in Nature communications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed, 1 pooled it
2.9field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Metrnl in health and disease: tissue-specific actions and signaling networks.Apoptosis : an international journal on programmed cell death · 2026
    Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

David E LeeDepartment of Medicine, Division of Hematology, Duke University School of Medicine, Durham, NC, 27710, USA.
Lauren K McKayDuke Molecular Physiology Institute, Duke University School of Medicine, Durham, NC, 27701, USA.
Akshay BarejaDepartment of Medicine, Division of Hematology, Duke University School of Medicine, Durham, NC, 27710, USA.
Yongwu LiDepartment of Biomedical Engineering, Duke University, Durham, NC, 27710, USA.
Alastair KhodabukusDepartment of Biomedical Engineering, Duke University, Durham, NC, 27710, USA.
Nenad BursacDepartment of Biomedical Engineering, Duke University, Durham, NC, 27710, USA.ORCID http://orcid.org/0000-0002-5688-6061
Gregory A TaylorGeriatric Research, Education, and Clinical Center, VA Health Care System, Durham, NC, 27701, USA.
Gurpreet S BahtDuke Molecular Physiology Institute, Duke University School of Medicine, Durham, NC, 27701, USA.
James P WhiteDepartment of Medicine, Division of Hematology, Duke University School of Medicine, Durham, NC, 27710, USA. james.white@duke.edu.ORCID http://orcid.org/0000-0003-2667-0806
Duke University · USUniversity of North Carolina at Chapel Hill · US

Funding

Stable therapy in Pompe disease through genome editingR01AR079223 · NIAMS · DUKE UNIVERSITY · PI KOEBERL, DWIGHT D · 2021 to 2025
$3.3M
IRGM proteins as regulators of inflammationR01AI148243 · NIAID · DUKE UNIVERSITY · PI COERS, JOERN, TAYLOR, GREGORY A · 2020 to 2024
$2.4M
Muscle-macrophage constructs for skeletal muscle repairR01AR070543 · NIAMS · DUKE UNIVERSITY · PI BURSAC, NENAD · 2016 to 2020
$1.9M
Role of IRGM proteins in immunity to enteric bacteriaR01AI145929 · NIAID · DUKE UNIVERSITY · PI TAYLOR, GREGORY A · 2019 to 2023
$1.6M
The AMPK/ULK1/p27Kip1 axis regulates autophagy and cell survival in aged satellite cellsK01AG056664 · NIA · DUKE UNIVERSITY · PI WHITE, JAMES P. · 2017 to 2022
$913k
NIAID NIH HHS R01 AI145929NIAID NIH HHS R01 AI148243NIAMS NIH HHS R01 AR070543NIAMS NIH HHS R01 AR079223NIA NIH HHS K01 AG056664
6 · The paper itself

Abstract

Pathologies associated with sarcopenia include decline in muscular strength, lean mass and regenerative capacity. Despite the substantial impact on quality of life, no pharmacological therapeutics are available to counteract the age-associated decline in functional capacity and/or, resilience. Evidence suggests immune-secreted cytokines can improve muscle regeneration, a strategy which we leverage in this study by rescuing the age-related deficiency in Meteorin-like through several in vivo add-back models. Notably, the intramuscular, peptide injection of recombinant METRNL was sufficient to improve muscle regeneration in aging. Using ex vivo media exchange and in vivo TNF inhibition, we demonstrate a mechanism of METRNL action during regeneration, showing it counteracts a pro-fibrotic gene program by triggering TNFα-induced apoptosis of fibro/adipogenic progenitor cells. These findings demonstrate therapeutic applications for METRNL to improve aged muscle, and show Fibro/Adipogenic Progenitors are viable therapeutic targets to counteract age-related loss in muscle resilience.

Indexed as

Muscle, SkeletalQuality of LifeAdipogenesisCytokinesStem CellsCytokines

Identifiers

PMID36494364
PMCPMC9734561
OpenAlexW4311664942

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.